StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30243% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Zetia (ezetimibe, legacy pre-Organon spin-off) by Quarter

Zetia (ezetimibe, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)

QuarterlyAnnual

Merck Zetia (ezetimibe, legacy pre-Organon spin-off): $2M in Q1 2021, down 200.0% from a year earlier. No newer figure appears in the documents we track.

Latest, Q1 2021
2
Period ended Mar 31, 2021
Change on a year earlier
-200.0%
-2 in Q1 2020
History
18 quarters
Since Q4 2016
Sources
13
Documents cited below

Where the Q1 2021 figure comes from

“|| Zetia | 92 | 145 | -37 | 2 | (2 | ) | -199 | 90 | 147 | -39”

Source: Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZetia (ezetimibe, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)Year on yearSource
Q1 2021Mar 31, 20212-200.0%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 202030.0%Form 10-K (filed 2021-02-25) ↗
Q3 2020Sep 30, 2020-1-120.0%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 2020-1-116.7%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 2020-2–Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2019Dec 31, 20193-72.7%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 20195-44.4%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2019Jun 30, 20196-25.0%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 20190-100.0%Form 10-Q (filed 2020-05-06) ↗
Q4 2018Dec 31, 201811-79.6%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2018Sep 30, 20189-86.2%Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2018Jun 30, 20188-93.4%Form 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2018Mar 31, 201817-84.7%Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗
Q4 2017Dec 31, 201754-83.9%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 201765–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2017Jun 30, 2017122–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗

Breakdown

What makes up zetia (ezetimibe, legacy pre-Organon spin-off)

Cite this data

StockData. (2026). Merck Zetia (ezetimibe, legacy pre-Organon spin-off) ($M), quarterly Q4 2016–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zetia-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.

See a number that looks wrong?